Literature DB >> 21077101

Glycogen hyperphosphorylation underlies lafora body formation.

Julie Turnbull1, Peixiang Wang, Jean-Marie Girard, Alessandra Ruggieri, Tony J Wang, Arman G Draginov, Alexander P Kameka, Nela Pencea, Xiaochu Zhao, Cameron A Ackerley, Berge A Minassian.   

Abstract

OBJECTIVE: Glycogen, the largest cytosolic macromolecule, acquires solubility, essential to its function, through extreme branching. Lafora bodies are aggregates of polyglucosan, a long, linear, poorly branched, and insoluble form of glycogen. Lafora bodies occupy vast numbers of neuronal dendrites and perikarya in Lafora disease in time-dependent fashion, leading to intractable and fatal progressive myoclonus epilepsy. Lafora disease is caused by deficiency of either the laforin glycogen phosphatase or the malin E3 ubiquitin ligase. The 2 leading hypotheses of Lafora body formation are: (1) increased glycogen synthase activity extends glycogen strands too rapidly to allow adequate branching, resulting in polyglucosans; and (2) increased glycogen phosphate leads to glycogen conformational change, unfolding, precipitation, and conversion to polyglucosan. Recently, it was shown that in the laforin phosphatase-deficient form of Lafora disease, there is no increase in glycogen synthase, but there is a dramatic increase in glycogen phosphate, with subsequent conversion of glycogen to polyglucosan. Here, we determine whether Lafora bodies in the malin ubiquitin ligase-deficient form of the disease are due to increased glycogen synthase or increased glycogen phosphate.
METHODS: We generated malin-deficient mice and tested the 2 hypotheses.
RESULTS: Malin-deficient mice precisely replicate the pathology of Lafora disease with Lafora body formation in skeletal muscle, liver, and brain, and in the latter in the pathognomonic perikaryal and dendritic locations. Glycogen synthase quantity and activity are unchanged. There is a highly significant increase in glycogen phosphate.
INTERPRETATION: We identify a single common modification, glycogen hyperphosphorylation, as the root cause of Lafora body pathogenesis.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21077101     DOI: 10.1002/ana.22156

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  53 in total

1.  Increased laforin and laforin binding to glycogen underlie Lafora body formation in malin-deficient Lafora disease.

Authors:  Erica Tiberia; Julie Turnbull; Tony Wang; Alessandra Ruggieri; Xiao-Chu Zhao; Nela Pencea; Johan Israelian; Yin Wang; Cameron A Ackerley; Peixiang Wang; Yan Liu; Berge A Minassian
Journal:  J Biol Chem       Date:  2012-06-05       Impact factor: 5.157

2.  Phosphorylation prevents polyglucosan transport in Lafora disease.

Authors:  Jean-Marie Girard; Scellig S D Stone; Hannes Lohi; Christophe Blaszykowski; Catia Teixeira; Julie Turnbull; Afra Wang; Arman Draginov; Peixiang Wang; Xiao Chu Zhao; Cameron A Ackerley; Paul W Frankland; Berge A Minassian
Journal:  Neurology       Date:  2012-05-23       Impact factor: 9.910

Review 3.  Glycogen phosphorylation and Lafora disease.

Authors:  Peter J Roach
Journal:  Mol Aspects Med       Date:  2015-08-13

4.  Lafora bodies in skeletal muscle are fiber type specific.

Authors:  J Turnbull; J-M Girard; N Pencea; X Zhao; T E Graham; P Wang; C A Ackerley; B A Minassian
Journal:  Neurology       Date:  2011-03-30       Impact factor: 9.910

5.  Dimeric quaternary structure of human laforin.

Authors:  Rajeshwer S Sankhala; Adem C Koksal; Lan Ho; Felix Nitschke; Berge A Minassian; Gino Cingolani
Journal:  J Biol Chem       Date:  2014-12-23       Impact factor: 5.157

6.  Skeletal Muscle Glycogen Chain Length Correlates with Insolubility in Mouse Models of Polyglucosan-Associated Neurodegenerative Diseases.

Authors:  Mitchell A Sullivan; Silvia Nitschke; Evan P Skwara; Peixiang Wang; Xiaochu Zhao; Xiao S Pan; Erin E Chown; Travis Wang; Ami M Perri; Jennifer P Y Lee; Francisco Vilaplana; Berge A Minassian; Felix Nitschke
Journal:  Cell Rep       Date:  2019-04-30       Impact factor: 9.423

7.  Modulators of Neuroinflammation Have a Beneficial Effect in a Lafora Disease Mouse Model.

Authors:  Belén Mollá; Miguel Heredia; Pascual Sanz
Journal:  Mol Neurobiol       Date:  2021-01-14       Impact factor: 5.590

Review 8.  [Lafora disease: a review of the literature].

Authors:  L Desdentado; R Espert; P Sanz; J Tirapu-Ustarroz
Journal:  Rev Neurol       Date:  2019-01-16       Impact factor: 0.870

9.  Laforin, a dual-specificity phosphatase involved in Lafora disease, is phosphorylated at Ser25 by AMP-activated protein kinase.

Authors:  Carlos Romá-Mateo; Maria Del Carmen Solaz-Fuster; José Vicente Gimeno-Alcañiz; Vikas V Dukhande; Jordi Donderis; Carolyn A Worby; Alberto Marina; Olga Criado; Antonius Koller; Santiago Rodriguez De Cordoba; Matthew S Gentry; Pascual Sanz
Journal:  Biochem J       Date:  2011-10-15       Impact factor: 3.857

Review 10.  Laforin, a protein with many faces: glucan phosphatase, adapter protein, et alii.

Authors:  Matthew S Gentry; Carlos Romá-Mateo; Pascual Sanz
Journal:  FEBS J       Date:  2012-03-16       Impact factor: 5.542

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.